【摘要】：目的:探討異基因造血干細胞移植(allogenic hematopoietic stem cell transplantation,allo-HSCT)后巨細胞病毒(CMV)感染的臨床特點和搶先治療的臨床意義。方法:對本院血液科2010年3月至2015年3月134例alloHSCT患者巨細胞病毒感染情況進行了回顧性分析,對移植后CMV感染的累積發(fā)生率、發(fā)生中位時間、相關危險因素,搶先治療有效率、轉(zhuǎn)陰中位時間以及移植患者長期生存率進行了統(tǒng)計分析。結(jié)果:Allo-HSCT后74/134例發(fā)生CMV血癥(55.2%),發(fā)生的中位時間為移植后34(14-283)d。單因素分析和多因素分析均顯示,預處理方案中應用ATG和合并Ⅱ-Ⅳ度a GVHD為CMV血癥的危險因素;85.1%(63/74)的患者經(jīng)抗病毒搶先治療后轉(zhuǎn)為陰性,轉(zhuǎn)陰中位時間為15(5-82)d,其中2例患者發(fā)生巨細胞病毒肺炎。未發(fā)生CMV血癥組移植患者5年生存率為66.3%,CMV血癥組移植患者5年生存率為49%,兩組間差異有統(tǒng)計學意義(P=0.041)。結(jié)論:預處理過程中使用ATG及合并Ⅱ-Ⅳ度a GVHD有可能增加allo-HSCT后CMV感染的發(fā)生率,搶先治療能有效阻止CMV血癥患者發(fā)病。
[Abstract]:Objective: to investigate the clinical features of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allogenic hematopoietic stem cell transplantation,allo-HSCT) and its clinical significance. Methods: a retrospective analysis of cytomegalovirus infection in 134 patients with alloHSCT from March 2010 to March 2015 was carried out. The cumulative incidence, median time, risk factors of CMV infection after transplantation were analyzed. The median time of negative conversion and long-term survival rate of transplant patients were statistically analyzed. Results: CMV occurred in 74 / 134 cases (55.2%) after Allo-HSCT, and the median time was 34 (14-283) days after transplantation. Univariate analysis and multivariate analysis showed that ATG and GVHD with degree 鈪，

本文編號：2330486